(Q38115190)

29 August 2017

title

Can bone loss in rheumatoid arthritis be prevented? (English)

1 reference

29 August 2017

0 references

M Vis

1

1 reference

29 August 2017

M Güler-Yüksel

series ordinal

2

1 reference

29 August 2017

W F Lems

series ordinal

3

1 reference

29 August 2017

language of work or name

English

0 references

publication date

18 June 2013

1 reference

Osteoporosis International

29 August 2017

published in

1 reference

29 August 2017

volume

24

1 reference

29 August 2017

issue

10

1 reference

29 August 2017

page(s)

2541-2553

1 reference

https://scigraph.springernature.com/pub.10.1007/s00198-013-2334-5

29 August 2017

exact match

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

The pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Osteoporosis and fractures in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Osteoimmunology and the effects of the immune system on bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

From bone biology to clinical outcome: state of the art and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Osteoimmunology and osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Assessment of hand bone loss in rheumatoid arthritis by high-resolution peripheral quantitative CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Resolution of inflammation induces osteoblast function and regulates the Wnt signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Osteoimmunology: Wnt antagonists: for better or worse?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Osteocyte control of osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Mechanosensation and transduction in osteocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Osteopenia: a diagnostic and therapeutic challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Estimation of bone mineral density by digital X-ray radiogrammetry: theoretical background and clinical testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Hand cortical bone mass and its associations with radiographic joint damage and fractures in 50-70 year old female patients with rheumatoid arthritis: cross sectional Oslo-Truro-Amsterdam (OSTRA) collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Bone mineral density by digital X-ray radiogrammetry is strongly decreased and associated with joint destruction in long-standing rheumatoid arthritis: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Risk of vertebral fracture in women with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Threefold increased risk of hip fractures with rheumatoid arthritis in Central Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Osteoporosis in inflammatory joint diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Injectable gold for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Management of glucocorticoid-induced osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Effects of glucocorticoids on radiological progression in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Effect of intra-articular corticosteroid injections and inflammation on periarticular and generalised bone loss in early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Changes in hand bone mineral density and the association with the level of disease activity in patients with rheumatoid arthritis: bone mineral density measurements in a multicenter randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Interleukin-6: discovery of a pleiotropic cytokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

CTLA-4 directly inhibits osteoclast formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2334-5

Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients

21 January 2018

1 reference

12 December 2020

Reduced bone mineral density in male rheumatoid arthritis patients: frequencies and associations with demographic and disease variables in ninety-four patients in the Oslo County Rheumatoid Arthritis Register

1 reference

12 December 2020

Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines

1 reference

12 December 2020

How to read radiographs according to the Sharp/van der Heijde method

1 reference

12 December 2020

Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis

1 reference

12 December 2020

Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade

1 reference

12 December 2020

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

1 reference

12 December 2020

Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial

1 reference

12 December 2020

Periarticular bone structure in rheumatoid arthritis patients and healthy individuals assessed by high resolution computed tomography

1 reference

12 December 2020

Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis

1 reference

12 December 2020

Prophylactic administration of abatacept prevents disease and bone destruction in a rat model of collagen-induced arthritis

1 reference

12 December 2020

Generalised bone loss in patients with early rheumatoid arthritis

1 reference

12 December 2020

Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis

1 reference

12 December 2020

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

12 December 2020

Healing phenomena of erosive changes in rheumatoid arthritis patients undergoing disease-modifying antirheumatic drug therapy

1 reference

12 December 2020

Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy

1 reference

12 December 2020

Identification of rheumatoid arthritis patients with vertebral fractures using bone mineral density and trabecular bone score

1 reference

12 December 2020

Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study

1 reference

12 December 2020

Serum osteocalcin levels in premenopausal rheumatoid arthritis patients

1 reference

12 December 2020

Increase of bone mineral density and anabolic variables in patients with rheumatoid arthritis resistant to methotrexate after cyclosporin A therapy

1 reference

12 December 2020

Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Norwegian Arthritis Study Group

1 reference

12 December 2020

Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989

1 reference

12 December 2020

Fractures after rheumatoid arthritis. A population-based study

1 reference

12 December 2020

Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register

1 reference

12 December 2020

Gold salts inhibit osteoclastic bone resorption in vitro

1 reference

12 December 2020

Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction

1 reference

12 December 2020

The short- and long-term effects of methotrexate on the rat skeleton

1 reference

12 December 2020

Circulating dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept

1 reference

12 December 2020

Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group

1 reference

12 December 2020

Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis

1 reference

12 December 2020

Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis

1 reference

12 December 2020

Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies

1 reference

12 December 2020

The effect of cyclosporin A administration and its withdrawal on bone mineral metabolism in the rat

1 reference

12 December 2020

Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis

1 reference

12 December 2020

Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor

1 reference

12 December 2020

Bisphosphonates and glucocorticoids: effects on bone quality

1 reference

12 December 2020

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial

1 reference

12 December 2020

MRI in early rheumatoid arthritis: synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression

1 reference

12 December 2020

Dickkopf-1 is a master regulator of joint remodeling

1 reference

12 December 2020

Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis

1 reference

12 December 2020

Bone structure in patients with low bone mineral density with or without vertebral fractures

1 reference

12 December 2020

Vertebral deformities in rheumatoid arthritis: a comparison with population-based controls

1 reference

12 December 2020

Effect of cyclosporine A on bone density in female rheumatoid arthritis patients: results from a multicenter, cross-sectional study.

1 reference

12 December 2020

Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis.

1 reference

12 December 2020

Mortality in rheumatoid arthritis: 2008 update.

1 reference

12 December 2020

Expression of osteoclast differentiation factor in rheumatoid arthritis

1 reference

12 December 2020

Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis

1 reference

12 December 2020

10.1007/S00198-013-2334-5

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1050519938

0 references

1 reference